ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Deniziaut, Gabrielle, Tille, Jean Christophe, Bidard, François-Clément, Vacher, Sophie, Schnitzler, Anne, Chemlali, Walid, Trémoulet, Laurence, Fuhrmann, Laetitia, Cottu, Paul, Rouzier, Roman, Bièche, Ivan, Vincent-Salomon, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341983/
https://www.ncbi.nlm.nih.gov/pubmed/27602491
http://dx.doi.org/10.18632/oncotarget.11819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341983/
https://www.ncbi.nlm.nih.gov/pubmed/27602491
http://dx.doi.org/10.18632/oncotarget.11819

Ejemplares similares